{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:49Z","timestamp":1789628509891,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The indications for postmastectomy radiation therapy (PMRT) after neoadjuvant chemotherapy (NAC) remain controversial. We aimed to identify prognostic factors and investigate subgroups in which PMRT could improve treatment outcomes. This study included 178 patients with clinical stage II\u2013III breast cancer who underwent mastectomy after NAC between May 2006 and December 2022. PMRT was administered to 149 (83.7%) patients. The median follow-up period was 64 months. The response to NAC, molecular subtype, and pathologic stage were independent predictors of treatment outcomes. The human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) molecular subtypes were associated with significantly higher pathologic complete response (ypCR) rates than the luminal HER2-negative subtype. Twenty-six patients (14.6%) achieved ypCR after NAC, and the overall response rate was 77.5%. Non-responders to NAC showed significantly worse 5-year locoregional control (LRC,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .01), progression-free survival (PFS,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01), and overall survival (OS,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01). Despite the relatively high likelihood of achieving ypCR, the TN subtype was significantly associated with worse 5-year LRC (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01), PFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .02), and OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .02) compared with the luminal HER2-negative and HER2-positive subtypes. With regard to the pathologic lymph nodal stage, PMRT did not confer significant benefits in terms of LRC (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .20), PFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .30), or OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .70) in the pathologically node-negative (ypN0) subgroup, but its use led to significant improvements in LRC (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01), PFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01), and OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .02) in the ypN1\u20133 subgroup. nonresponse to NAC and TN molecular subtype were poor prognostic factors for survival. PMRT was associated with improved survival outcomes in patients with residual lymph nodes following NAC and mastectomy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050351","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:06:07Z","timestamp":1787331967000},"page":"e50351","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-8674","authenticated-orcid":false,"given":"Hye Jin","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Incheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Incheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Kang","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Incheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Incheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis.","volume":"10","author":"Benitez Fuentes","year":"2024","journal-title":"JAMA Oncol"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","article-title":"Progress in adjuvant chemotherapy for breast cancer: an overview.","volume":"13","author":"Anampa","year":"2015","journal-title":"BMC Med"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jamcollsurg.2015.02.011","article-title":"Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.","volume":"220","author":"Killelea","year":"2015","journal-title":"J Am Coll Surg"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1200\/JCO-25-01747","article-title":"Postmastectomy radiation therapy: an ASTRO-ASCO-SSO clinical practice guideline.","volume":"43","author":"Jimenez","year":"2025","journal-title":"J Clin Oncol"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.3390\/cancers13246205","article-title":"The impact of post-mastectomy radiotherapy on survival outcomes in breast cancer patients who underwent neoadjuvant chemotherapy.","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27.","volume":"30","author":"Mamounas","year":"2012","journal-title":"J Clin Oncol"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast cancer.","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/annonc\/mdw046","article-title":"The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.","volume":"27","author":"Rusthoven","year":"2016","journal-title":"Ann Oncol"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"24848","DOI":"10.18632\/oncotarget.6664","article-title":"The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB.","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"605750","DOI":"10.3389\/fonc.2020.605750","article-title":"Trastuzumab provides a comparable prognosis in patients with HER2-positive breast cancer to those with HER2-negative breast cancer: Post hoc analyses of a aandomized controlled trial of post-mastectomy hypofractionated radiotherapy.","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1245\/s10434-023-13938-x","article-title":"Distinct prognosis of minimal residual disease according to breast cancer subtype in patients with breast or nodal pathologic complete response after neoadjuvant chemotherapy.","volume":"30","author":"Go","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.","volume":"170","author":"Haque","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.21873\/anticanres.15051","article-title":"Clinical outcomes among major breast cancer subtypes after neoadjuvant chemotherapy: impact on breast cancer recurrence and survival.","volume":"41","author":"Orsaria","year":"2021","journal-title":"Anticancer Res"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijrobp.2020.06.028","article-title":"Postmastectomy radiation therapy based on pathologic nodal status in clinical node-positive stage II to III breast cancer treated with neoadjuvant chemotherapy.","volume":"108","author":"Huang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"592","DOI":"10.4143\/crt.2022.998","article-title":"Impact of postmastectomy radiation therapy on breast cancer patients according to pathologic nodal status after modern neoadjuvant chemotherapy.","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"R24-20260917","first-page":"6632635","article-title":"Impact of postmastectomy radiotherapy on locoregional control and disease-free survival in patients with breast cancer treated with neoadjuvant chemotherapy.","volume":"2021","author":"Zhang","year":"2021","journal-title":"J Oncol"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ijrobp.2010.12.054","article-title":"Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy.","volume":"82","author":"Le Scodan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijrobp.2013.09.021","article-title":"The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).","volume":"88","author":"Shim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/jso.24551","article-title":"Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy.","volume":"115","author":"Kantor","year":"2017","journal-title":"J Surg Oncol"},{"key":"R28-20260917","first-page":"27","article-title":"Effect of clinical and treatment factors on survival outcomes of triple negative breast cancer patients.","volume":"12","author":"Wen","year":"2020","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2020.09.043","article-title":"Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03.","volume":"154","author":"Choi","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:01:52Z","timestamp":1789624912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050351"}},"subtitle":["A retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":28,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050351","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2024-04-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}